New 'Alpha' radiation therapy tested for Tough-to-Treat cancers
NCT ID NCT06427798
Summary
This study is testing a new targeted radiation drug for adults whose gastrointestinal neuroendocrine tumors (GI NET) or adrenal tumors (pheochromocytoma/paragangliomas) have spread and cannot be removed by surgery, and have already been treated with a similar type of radiation therapy. The new drug uses a stronger type of radiation (alpha particles) designed to better kill cancer cells that have returned. The main goals are to find the safest dose and see if the treatment shrinks tumors in people who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.